{"blog": [], "keywords": [{"value": "Clinical Trials", "name": "subject", "rank": "1", "is_major": "N"}, {"value": "Bristol Myers Squibb Company", "name": "organizations", "rank": "2", "is_major": "N"}, {"value": "Merck & Company Inc", "name": "organizations", "rank": "3", "is_major": "N"}, {"value": "Lung Cancer", "name": "subject", "rank": "4", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/08/06/business/dealbook/bristol-myers-squibbs-hubris-cost-it-21-billion.html", "document_type": "article", "byline": {"person": [{"lastname": "CYRAN", "firstname": "Robert", "role": "reported", "organization": "", "rank": 1}], "original": "By ROBERT CYRAN"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/08/06/business/06DRUG/06DRUG-thumbWide.jpg", "legacy": {"wide": "images/2016/08/06/business/06DRUG/06DRUG-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/08/06/business/06DRUG/06DRUG-articleLarge.jpg", "legacy": {"xlarge": "images/2016/08/06/business/06DRUG/06DRUG-articleLarge.jpg", "xlargeheight": "401", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 401}, {"url": "images/2016/08/06/business/06DRUG/06DRUG-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/08/06/business/06DRUG/06DRUG-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "413", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "Investors wiped off billions in value after Bristol\u2019s cancer drug trial failed. The stumble will allow its more cautious rival to clean up.", "pub_date": "2016-08-06T04:00:00+0000", "news_desk": "Business", "headline": {"kicker": "Breakingviews", "main": "Bristol-Myers Squibb\u2019s Hubris Cost It $21 Billion", "content_kicker": "Breakingviews"}, "print_page": null, "snippet": "Investors wiped off billions in value after Bristol\u2019s cancer drug trial failed. The stumble will allow its more cautious rival to clean up....", "_id": "57aa09aa95d0e021d797eeee", "slideshow_credits": null, "abstract": null}